然而，三星Bioepis近日与一家未透露名称的“垂直整合健康集团”达成合作，提前以自有品牌销售其仿制药Pyzchiva，并于本周一正式上市。强生指控此举“明显违反协议”，构成“秘密且故意的违约行为”，可能对Stelara的市场份额造成“不可逆的损害”。

Biocon share price rose by 2.5% after its arm launched Yesintek, a biosimilar for autoimmune disorders in the US. Approved ...

Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...

The company, along with its subsidiary NTPC Green Energy, has entered into multiple MoUs with the Madhya Pradesh government ...

Samsung Bioepis allegedly entered into an agreement with a third-party health company, allowing it to market its own private ...

Biocon Biologics launches Yesintek biosimilar to Stelara in US: Our Bureau, Bengaluru Tuesday, February 25, 2025, 15:40 Hrs [IST] Biocon Biologics has announced that Yesintek (ust ...

YESINTEK is a monoclonal antibody that disrupts IL-12 and IL-23 mediated signaling associated immune mediated diseases.

Biocon share rose after Biocon Biologics, a subsidiary of Biocon, announced that Yesintek (ustekinumab-kfce) is now available ...

Biocon Limited informed on Monday that its subsidiary Biocon Biologics announced the US market availability of YESINTEK ...

Biocon Biologics has launched YESINTEK, a biosimilar to Stelara, in the United States for treating chronic autoimmune ...

NTPC along with its arm NTPC Green Energy signed multiple MoUs with Madhya Pradesh government to invest over Rs 2 lakh crore ...

A number of stocks are set to be in focus during the coming session on Dalal Street, including NTPC, NTPC Green, SBI Card and ...